A carregar...
BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors
The bromodomain and extra-terminal domain (BET) proteins are promising therapeutic targets to treat refractory solid tumors; however, inherent resistance remains a major challenge in the clinic. Recently, the emerging role of the oncoprotein B cell lymphoma 6 (BCL6) in tumorigenesis and stress respo...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7773368/ https://ncbi.nlm.nih.gov/pubmed/33393503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI133090 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|